CD19 and neoplasm: In contrast, the CD19 CAR-T cell group showed a modest anti-leukemic effect, which was enhanced in combination with CHZ868, as evidenced by live tumor imaging (Fig. 5a, b), prolonged survival (Fig. 5c), and the number of viable tumor cells in the bone marrow on day 21 (Fig. 5d).